NeuroVigil is fortunate to enjoy the support and encouragement of visionaries the likes of Stephen Hawking, Elon Musk, Irwin Jacobs, Howard Morgan, fmr. Bell Labs Chief Scientist Ron Graham, Nobel laureates Roger Guillemin and  Sydney Brenner and many others...


"Neurovigil is a global neurotechnology pioneer which develops non-invasive brain monitors for many applications. Deep Science, excellently applied into different fields. This is the highest ranked company in value and reputation I ever saw at this stage."
Sven Gabor Janszky
Chairman, 2b AHEAD ThinkTank and 2b AHEAD Ventures GmbH

"Francis Crick, co-discoverer of the structure of the DNA molecule, was one of the greatest biologists of the 20th century. It is a testament to Dr. Low's standing in the field and to his exceptional promise that he was selected to lead the first conference named in Dr. Crick's honor... His presence in the United States is an asset to the entire medical and research community."
Sonia Ancoli-Israel, PhD
Professor of Psychiatry Director, Gillin Sleep and Chronobiology Research Center, UCSD School of Medicine

"NeuroVigil is building the first comprehensive interface between the self and the brain."
Peter H. Diamandis, MD
Chairman/CEO, X Prize Foundation
Chairman, Co-Founder, Singularity University

"Neurovigil has a unique technology and platform that is at the front line of the EEG acquisition and data handling...The company has strong science, good leadership and a bold vision, to the benefit of patients and drugmakers helping them worldwide."
Executive Director of Neuroscience and Translational Medicine
Large Pharmaceutical Company

"Companies like NeuroVigil and entrepreneurs of Dr. Low's intellect and bold vision embody DFJ's mission to identify, serve, and provide capital for extraordinary entrepreneurs anywhere who are determined to change the world... The societal returns on believing in Dr. Low and NeuroVigil are well worth any investment."
Timothy C. Draper
Managing Director, Draper Fisher Jurvetson

"I believe that his achievements in monitoring and ultimately managing brain activity during sleep are likely to have a big impact on people's health and well-being over time."
Esther Dyson
Chairman, EDventure Holdings

"Dr. Low's methodology could revolutionize the manner in which electrophysiological studies are conducted in humans and non-human animals alike."
David B. Edelman, PhD
Associate Fellow in Experimental Neurobiology, The Neurosciences Institute

"Dr. Low's clarity of vision is apparent in the rapidity with which he has been able to engineer a deceptively simple medical device to take advantage of mathematically complex algorithms that he developed. I understand that these have applications well outside the field that they were developed for, but their utility in the field of brain imaging is remarkable enough. Basically he has found a way to mine wavelengths that have been completely ignored in the first few decades of brain imaging, with dr amatic increases in quantitative precision and resolution of abnormal states. The achievement is singular, well outside the norm for a doctoral thesis."
Greg Gibson, PhD
Professor, School of Biology, Georgia Tech

"Everything possible should be done to help him continue his historic mission."
Ron Graham, PhD
Chief Scientist Emeritus, Bell Labs
Treasurer Emeritus, U.S. National Academy of Sciences
President Emeritus, American Mathematical Society and the Mathematical Association of America
Chair of Computer and Information Sciences in the Computer Science and Engineering Department
Distinguished Professor of Mathematics
Chief Scientist of the California Institute of Telecommunications and Information Technology, UCSD

"Philip discovered a fundamentally new way to assess brain activity... This technology is having tremendous impact."
Roger Guillemin, PhD
Nobel Laureate in Physiology and Medicine
Interim President Emeritus, The Salk Institute for Biological Studies

"His contributions are transforming our ability to non-invasively monitor the brainwaves of many millions of individuals that suffer from Alzheimer's and other brain-related disorders."
Piyush Gupta, PhD
Assistant Professor of Biology, MIT

"An idea ahead of its time requires a person ahead of his time. Dr. Low is that person as he is singularly suited to keep leading NeuroVigil into one of the top medical companies in America. Dr. Low is an irreplaceable asset to our nation's economic, societal and medical interests."
Gregory S. Horowitt
Managing Director, T2 Venture Capital
Co-founder, UCSD Global Connect

"His work on non-invasive monitoring of real-time brain activity using a single-channel EEG and inventing an algorithm to accurately and quickly determine sleep state has earned many awards for ingenuity and elegance and is the basis of his founding in the United States the neurodiagnostics company, NeuroVigil... At his doctoral dissertation (which I was privileged to attend), he expanded on his work on birds and on the further enhancements of signal-processing to support the broad range of applications [to health problems]... I believe Dr. Low is a significant asset to the United States."
Irwin M. Jacobs, PhD
Founding Chairman and CEO, Qualcomm, Inc.
Former Professor, MIT and UCSD
Chairman of the Board, Salk Institute and National Academy of Engineering

"As a result of Dr. Low's leadership. NeuroVigil is a game-changing institution at the cutting edge of Neuroscience innovation with a growing list of clients, spread through four continents and across the military-industrial complex, all the way from Roche to Stephen Hawking."
Naveen Jain
CEO, Intelius

"If we are to recover from our current economic recession, we need rare scientist-entrepreneurs such as Dr. Philip Low to successfully translate discoveries in the basic sciences into jobs and useful products."
Christof Koch, PhD
Chief Scientific Officer, Allen Institute for Brain Science
Lois and Victor Troendle Professor of Cognitive & Behavioral Biology, California Institute of Technology

"It is the rare individual who is so outstanding that his retention merits consideration of our "national interests". Philip is such a person, and his continued presence in the United States will benefit the health of our people and of our economy."
Jay D. Kranzler, MD, PhD
Global Head - External R & D Innovation - Neurosciene, Pain and Sensory Disorders at Pfizer

"His Ph.D. work at the Salk Institute attracted me to him, and I have been an investor and advisor to his company. This pioneering work on non-invasive sleep monitoring, with elegant mathematics and computational techniques to do this with far fewer sensors than previously done, has proven of great use in looking for how sleep states reflect other actual and likely future disease states in the body."
Howard Lee Morgan, PhD
Managing Partner, First Round Capital

"NeuroVigil has captured the attention of Silicon Valley... Dr. Low's expertise, intellect and drive currently place him and his company in a league of their own. The technology has the transformative promise of only a handful of the most successful technology companies the genesis of which I witnessed during my last twenty years in Silicon Valley."
Larry Marshall, PhD
Southern Cross Ventures

"The company has the capability of generating the most information about a person's brain while at the same [time], putting the least on a person's head. The innovation therein lies in a patented algorithm Dr. Low has developed when he was still a graduate student at The Salk Institute for Biological Studies... This is one of the rare examples when the neuroscience research of a single person, namely Dr. Low, is having an immediate effect on preventive care. This discovery has the potential to revolutionize the way neurological patients are assessed and when they are treated, a significant contribution to medicine."
Michael McCullough, M.D., M.Sc.
Assistant Clinical Professor of Emergency Medicine, UCSF

"Dr. Low single-handedly merged three important research foci: EEG, sleep and computational techniques. He discovered a map of brain activity wherein seconds of EEGs are represented by dots, which cluster in different places depending on which brain state a person is in. The group activity from the 100 Billion neurons in each of our brains is, as it turns out, not noisy at all, and its structure can be elegantly teased out, in a completely unsupervised manner, without knowledge of the species or the number and statistical distribution of brain rhythms. This is an immense achievement."
Head, Modeling & Simulation, Neuroscience
Large Pharmaceutical Company

"NeuroVigil, under Dr. Low's leadership, is the only company I know that has a true potential to completely revolutionize neuroscience. That is because Dr. Low is committed to building a platform of devices, machine learning algorithms and databases which accurately measure pathologies across time, before symptoms and major, mostly irreversible, damage in the brain occur. Given that many neuropathologies share overlapping symptoms, exactitude in neuroscience actually can be derived from studying multiple pathologies through the same platform, which is exactly what Dr. Low and NeuroVigil are doing."
Elon Musk
CEO & Chairman, SpaceX
CEO & Chairman, Tesla Motors
Chairman, SolarCity

"From his bold dissertation thesis, which literally created a new paradigm for the study of brain waves, to his founding of NeuroVigil so soon afterward as a convincing demonstration of his belief in the marketability of his findings, Philip has consistently forged new paths. His iBrain system currently represents the best minimal-channel alternative to traditional electroencephalography, and because of its increased functionality, the likely successor to this mainstay of medicine. So far, the iBrain has proven to be an invaluable adjunct to pharmacological clinical trial research. Unintended adverse effects involving the central nervous system can now be identified sooner and at significantly reduced cost to the developer. Yet, despite NeuroVigil's success to date, I believe that the most significant applications of this technology are yet to come. The future will see home-based biometrics becoming a central feature of modern medical practice as screening, monitoring and tracking of innovative health data evolve into standard components of the electronic medical record. Central to these assessments will be a brain health status measurement that has both diagnostic and prognostic validity and, given their current prominence in this area, NeuroVigil will likely be the industry leader."
Mario A. Orlandi, PhD
Executive Director, Technology Assessment, Johnson & Johnson

"These techniques are translational as they have been successfully applied all the way from birds to rodents to humans, including in Depression, Autism, ALS and many other CNS pathologies...The brain is the most complex machine in the universe, and if Pharmaceutical companies are to do an effective job at treating it better with fewer side effects and in asymptomatic patients, we will need to use scalable early detection tools, which open up more dimensions of research and give us an opportunity to address changes in the brain before they become full blown pathologies. Dr. Low and NeuroVigil offer the Pharmaceutical industry such tools, a significant contribution..."
Sr. Vice President
Head of Neuroscience, Clinical Research and Exploratory Development
Another Large Pharmaceutical Company

"San Diego is proud to be home to hundreds of innovative startups in the biotechnology, medical device and wireless areas. NeuroVigil, however, is truly a standout among them. The neurotechnology platform Dr. Low developed is clearly leading a revolution in disease treatment by improving diagnosis, drug efficacy analysis and health monitoring."
Jerry Sanders
Mayor, City of San Diego

"Dr. Philip Low, then a graduate student in Computational Neuroscience at the Salk Institute for Biological Studies in California, clearly demonstrated it was possible to analyze an entire night of sleep with only a pair of electrodes on the patient's head. Moreover, the techniques described by Dr. Low produce a clear map of brain activity, derived mathematically from a single electroencephalogram (EEG) channel... A clear advantage of Dr. Low's technique is that it requires only a single channel, is non-invasive and is applicable to humans as well. Dr. Low's work has truly revolutionized the field of sleep medicine by solving seemingly insurmountable problems and opening new ways to make sense of brain activity during sleep."
Thomas E. Scammell, M.D.
Professor of Neurology, Harvard Medical School
Physician, Associate Professor, Department of Neurology, Beth
Israel Deaconess Medical Center

"NeuroVigil will bring this remarkable breakthrough to the marketplace, where it has promise to revolutionize the screenings of drugs and the diagnosis of sleep disorders... his company is poised to make a major contribute to the economy of the US."
Terrence J. Sejnowski, PhD
Francis Crick Professor, Salk Institute
Investigator, Howard Hughes Medical Instititute
University of California, San Diego

"The single channel scoring system allows completely objective scoring of sleep states. It also reveals aspects of sleep structure that had not been described before and which can be described as newly defined sleep states. This is in contrast to commercial sleep scoring systems which have been designed to classify EEG patterns into previously defined sleep states. This is very important and creative work. His recent paper on sleep in the zebra finch sets a new standard for the phylogenetic studies of sleep. Dr. Low is an extremely impressive researcher, combining mathematical sophistications with a keen knowledge of the literature and a creative synthesis of this literature. He has operated independently and with the highest degree of creativity in his research."
J.M. Siegel, PhD
Chief of Neurobiology Research
Professor of Psychiatry and Biobehavioral Sciences
UCLA School of Medicine

"Dr. Low's graduate work on brain oscillations has put to rest the long supported notion, held by researchers and clinicians alike, that the Neocortex was necessary for highly evolved sleep patterns. Dr. Low's groundbreaking work on humans, which has been validated in clinical trials in the United States and in Germany, has shown that a single electrode on person's head was sufficient to replace existing complicated clinical setups in sleep labs and could furthermore be used to identify new classes of sleep derived neurological biomarkers. This led to Dr. Low's discovery of a New Human Sleep stage. A portion of this work was elegantly summarized in his Ph.D. thesis: "A New Way To Look At Sleep" PS Low, Ph.D. thesis, UC San Diego, 2007... The company [NeuroVigil], which has recently garnered top awards for its technology and business model, now has numerous research contracts with leading pharmaceutical companies to systematically evaluate the efficacy and danger of pre-market drugs -a technology which will save many lives."
Eric J. Topol, M.D.
Director, Scripps Translational Science Institute
Chief Academic Officer, Scripps HealthProfessor of Translational Genomics, The Scripps Research Institute

"The technology holds great promise for monitoring patients in remote locations, and even forward deployed battlefield medical facilities."
Director of Research and Development, US Navy

"Dr. Low is building an IP powerhouse in the Neurotech space and also launching a consortium with strategic partners... exciting venture."
Business & Corporate Development, Verily

"NeuroVigil's approach to preventative healthcare is both scientifically valid and logistically viable."
Pascale Witz
President & CEO Medical Diagnostics
GE Healthcare

"One of the most important growing areas of medicine is our growing ability to measure new signals from the body and interpret them in order to make important diagnoses earlier and more accurately than we can today. Dr. Low's inventions, research, and commercialization of such an approach for brain diseases is unique and in my opinion one of the most important approaches happening anywhere in the world."
Roni Zeiger, PhD
Chief Health Strategist, Google, Inc.